Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Draft scope assessment: unclear. Attached because the study's own record names HER2 and describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Confirmed objective response rate (ORR), defined as the proportion of participants with complete response (CR) or partial response (PR), was assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Full Analysis Set includes all subjects for whom study treatment was assigned by randomization

→

secondary · POSTED

Confirmed objective response rate (ORR), defined as the percentage of participants with complete response (CR) or partial response (PR), will be assessed by the Investigator based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Full Analysis Set includes all subjects for whom study treatment was assigned by randomization

→

secondary · POSTED

Duration of response (DoR) is defined as the time from the initial response (complete response \[CR\] or partial response \[PR\]) until documented tumor progression or death from any cause. DoR is only defined for participants who achieved confirmed CR or PR. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.

Full Analysis Set includes all subjects for whom study treatment was assigned by randomization. From the Full Analysis Set, 47 participants had a confirmed CR or PR in T-DXd 5.4 mg/kg arm, and 28 participants in T-DXd 6.4 mg/kg arm

→

secondary · POSTED

Disease control rate (DCR) is the sum of complete response (CR), partial response (PR), and stable disease (SD) rates. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.

Full Analysis Set includes all subjects for whom study treatment was assigned by randomization

→

secondary · POSTED

Progression-free survival (PFS) is defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on blinded independent central review (BICR) and investigator assessment.

Full Analysis Set includes all subjects for whom study treatment was assigned by randomization

→

secondary · POSTED

Overall survival (OS) is defined as the time from date of randomization until death from any cause.

Full Analysis Set

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

EORTC QLQ · Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores

Score direction: Higher is better, according to the source. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id: NCT04644237
qol key: qol-0011
source section id: NCT04644237-om-0011
source outcome index: 11
instrument: EORTC QLQ
instrument basis: matched 'eortc' in the study's own wording
scale title: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores
measure definition: The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms. The QLQ-LC13 is a 13-item questionnaire designed to assess lung cancer-related symptoms and treatment side effects. The scales ranges from 1=not at all to 4=very much. The summation of scores range from 0 to 100, where higher scores represent increasing symptoms levels. scales.
time frame: At baseline and at end of treatment 40-day follow-up visit
analysis role: secondary
reporting status: POSTED
higher is better: 1
direction quote: Higher scores for functioning scales and global health status indicate a better
population note: Full Analysis Set
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

EORTC QLQ · Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores

Score direction: Higher is better, according to the source. Direction is never inferred from an instrument name.

release id: clinical-indications-draft-1
disease state id: ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id: NCT04644237
qol key: qol-0012
source section id: NCT04644237-om-0012
source outcome index: 12
instrument: EORTC QLQ
instrument basis: matched 'eortc' in the study's own wording
scale title: Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores
measure definition: The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.
time frame: At baseline and at end of treatment 40-day follow-up visit
analysis role: secondary
reporting status: POSTED
higher is better: 1
direction quote: Higher scores for functioning scales and global health status indicate a better
population note: Full Analysis Set
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Open the exact result →

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id: NCT04644237
trial label: Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
applicability: unclear
applicability note: Attached because the study's own record names HER2 and describes metastatic disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: regulator-cited
discovery note: Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.
outcome Count: 6
harms Count: 2
qol Count: 2

outcomes

release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0000
source section id
NCT04644237-om-0000
source outcome index
0
endpoint
Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
endpoint definition
Confirmed objective response rate (ORR), defined as the proportion of participants with complete response (CR) or partial response (PR), was assessed by blinded independent central review (BICR) based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.
time origin
9 months after the last participant is randomized to data cut off, up to approximately 21 months
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Full Analysis Set includes all subjects for whom study treatment was assigned by randomization
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0001
source section id
NCT04644237-om-0001
source outcome index
1
endpoint
Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors
endpoint definition
Confirmed objective response rate (ORR), defined as the percentage of participants with complete response (CR) or partial response (PR), will be assessed by the Investigator based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.
time origin
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Full Analysis Set includes all subjects for whom study treatment was assigned by randomization
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0002
source section id
NCT04644237-om-0002
source outcome index
2
endpoint
Duration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
endpoint definition
Duration of response (DoR) is defined as the time from the initial response (complete response \[CR\] or partial response \[PR\]) until documented tumor progression or death from any cause. DoR is only defined for participants who achieved confirmed CR or PR. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.
time origin
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Full Analysis Set includes all subjects for whom study treatment was assigned by randomization. From the Full Analysis Set, 47 participants had a confirmed CR or PR in T-DXd 5.4 mg/kg arm, and 28 participants in T-DXd 6.4 mg/kg arm
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0003
source section id
NCT04644237-om-0003
source outcome index
3
endpoint
Disease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
endpoint definition
Disease control rate (DCR) is the sum of complete response (CR), partial response (PR), and stable disease (SD) rates. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.
time origin
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Full Analysis Set includes all subjects for whom study treatment was assigned by randomization
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0004
source section id
NCT04644237-om-0004
source outcome index
4
endpoint
Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer
endpoint definition
Progression-free survival (PFS) is defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on blinded independent central review (BICR) and investigator assessment.
time origin
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Full Analysis Set includes all subjects for whom study treatment was assigned by randomization
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0005
source section id
NCT04644237-om-0005
source outcome index
5
endpoint
Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors
endpoint definition
Overall survival (OS) is defined as the time from date of randomization until death from any cause.
time origin
9 months after the last participant is randomized or later to data cut off, up to approximately 35 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Full Analysis Set
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0000
arm key
OG000
arm label
Trastuzumab Deruxtecan 5.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
102
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0000
arm key
OG001
arm label
Trastuzumab Deruxtecan 6.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
50
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0001
arm key
OG000
arm label
Trastuzumab Deruxtecan 5.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
102
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0001
arm key
OG001
arm label
Trastuzumab Deruxtecan 6.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
50
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0001#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0002
arm key
OG000
arm label
Trastuzumab Deruxtecan 5.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0002
arm key
OG001
arm label
Trastuzumab Deruxtecan 6.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
28
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0002#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0003
arm key
OG000
arm label
Trastuzumab Deruxtecan 5.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
102
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0003
arm key
OG001
arm label
Trastuzumab Deruxtecan 6.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
50
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0003#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0004
arm key
OG000
arm label
Trastuzumab Deruxtecan 5.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
102
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0004
arm key
OG001
arm label
Trastuzumab Deruxtecan 6.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
50
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0004#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0005
arm key
OG000
arm label
Trastuzumab Deruxtecan 5.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
102
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0005#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
outcome key
om-0005
arm key
OG001
arm label
Trastuzumab Deruxtecan 6.4 mg/kg
regimen
Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).
analyzed count
50
analyzed unit
Participants
is comparator
Source null
source pointer
NCT04644237-om-0005#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
harm key
EG000
source section id
NCT04644237-ae
event group key
EG000
event group label
Trastuzumab Deruxtecan 5.4 mg/kg
serious affected
42
serious at risk
101
other affected
101
other at risk
101
frequency threshold
5
collection period
Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up to approximately 35 months
event definition
A treatment-emergent adverse event (TEAE) was defined as an AE that occurred, having been absent before the first dose of study drug, or had worsened after initiating study treatment up until 47 days after the last dose of the study treatment. All-Cause Mortality was assessed in the Full Analysis Set, all adverse events were assessed in the Safety Analysis Set
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
harm key
EG001
source section id
NCT04644237-ae
event group key
EG001
event group label
Trastuzumab Deruxtecan 6.4 mg/kg
serious affected
26
serious at risk
50
other affected
50
other at risk
50
frequency threshold
5
collection period
Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up to approximately 35 months
event definition
A treatment-emergent adverse event (TEAE) was defined as an AE that occurred, having been absent before the first dose of study drug, or had worsened after initiating study treatment up until 47 days after the last dose of the study treatment. All-Cause Mortality was assessed in the Full Analysis Set, all adverse events were assessed in the Safety Analysis Set
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
qol key
qol-0011
source section id
NCT04644237-om-0011
source outcome index
11
instrument
EORTC QLQ
instrument basis
matched 'eortc' in the study's own wording
scale title
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores
measure definition
The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms. The QLQ-LC13 is a 13-item questionnaire designed to assess lung cancer-related symptoms and treatment side effects. The scales ranges from 1=not at all to 4=very much. The summation of scores range from 0 to 100, where higher scores represent increasing symptoms levels. scales.
time frame
At baseline and at end of treatment 40-day follow-up visit
analysis role
secondary
reporting status
POSTED
higher is better
1
direction quote
Higher scores for functioning scales and global health status indicate a better
population note
Full Analysis Set
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-small-cell-lung-cancer-bizengri-4710e9b9
nct id
NCT04644237
qol key
qol-0012
source section id
NCT04644237-om-0012
source outcome index
12
instrument
EORTC QLQ
instrument basis
matched 'eortc' in the study's own wording
scale title
Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores
measure definition
The EORTC QLQ-C30 consists of 30 questions assessing global health-related quality of life, five aspects of subject functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and six single-items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher scores for functioning scales and global health status indicate a better level of functioning while higher scores on the symptom and single-item scales indicate a higher level of symptoms.
time frame
At baseline and at end of treatment 40-day follow-up visit
analysis role
secondary
reporting status
POSTED
higher is better
1
direction quote
Higher scores for functioning scales and global health status indicate a better
population note
Full Analysis Set
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

setting source links

Preserved source evidence · Not medical advice